{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:10:28Z","timestamp":1789035028003,"version":"build-2803163510"},"reference-count":198,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Immune checkpoints (ICPs) are essential regulators of immune homeostasis, maintaining the balance between effective immune responses and tolerance to self-antigens. Dysregulation of ICP signaling may contribute to impaired immune surveillance, immune evasion, chronic inflammation, autoimmunity, persistent infections, and tumor progression. Consequently, ICP molecules are increasingly recognized not only as therapeutic targets but also as potential diagnostic, prognostic, predictive, and treatment-monitoring biomarkers. This review provides a comprehensive overview of the biological functions, signaling mechanisms, and clinical significance of major co-inhibitory and co-stimulatory ICP pathways, including PD-1\/PD-L1\/PD-L2, CTLA-4\/CD28\/CD80\/CD86, LAG-3, TIM-3, TIGIT, BTLA, VISTA, ICOS, OX40, 4-1BB, GITR, CD27, CD40, and CD2, together with their corresponding ligands. Particular emphasis is placed on their biomarker potential in cancer and immune-mediated diseases. In addition, the review presents a bioinformatic characterization of ICP receptors and ligands based primarily on data available in UniProtKB and complementary bioinformatic resources. The analysis includes protein sequence length, molecular weight, theoretical isoelectric point, amino acid composition, subcellular localization, conserved and functional domains, protein family classification, post-translational modifications, isoforms, and selected structural features. Collectively, the available evidence indicates that ICPs constitute a structurally and functionally diverse group of immunoregulatory molecules with substantial biomarker potential. Integrating their molecular, structural, functional, and bioinformatic characteristics may improve disease classification, prognosis, patient stratification, treatment selection, and therapeutic monitoring. Such an integrated approach may also support the identification of novel biomarkers and therapeutic targets and contribute to the further development of precision and personalized medicine.<\/jats:p>","DOI":"10.3390\/antib15050084","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:03Z","timestamp":1789031583000},"page":"84","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Architecture and Clinical Landscape of Immune Checkpoint Receptors and Ligands"],"prefix":"10.3390","volume":"15","author":[{"given":"Milena","family":"Czosnek","sequence":"first","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"},{"name":"Student Research Group of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Sowa","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"},{"name":"Student Research Group of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ucja","family":"Rolek","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"},{"name":"Student Research Group of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Grywalska","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-1396","authenticated-orcid":false,"given":"Sebastian","family":"Mertowski","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-6659","authenticated-orcid":false,"given":"Paulina","family":"Mertowska","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e70196","DOI":"10.1002\/iid3.70196","article-title":"Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications","volume":"13","author":"Majidazar","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., and Boussiotis, V.A. (2023). Immune-Related Adverse Effects of Checkpoint Immunotherapy and Implications for the Treatment of Patients with Cancer and Autoimmune Diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1197364"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Duhamel, M., and Salzet, M. (2025). Self or nonself: End of a dogma?. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1595764"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Giri, S., and Batra, L. (2025). Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications. Vaccines, 13.","DOI":"10.3390\/vaccines13020205"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1002\/mco2.714","article-title":"The interaction of innate immune and adaptive immune system","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Arneth, B. (2025). Molecular Mechanisms of Immune Regulation: A Review. Cells, 14.","DOI":"10.3390\/cells14040283"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s12276-025-01527-9","article-title":"Targeting immunosenescence and inflammaging: Advancing longevity research","volume":"57","author":"Nguyen","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_8","unstructured":"Sabir, S., and Jan, A. (2026, July 15). Physiology, Immune Response, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539801\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next Generation of Immune Checkpoint Therapy in Cancer: New Developments and Challenges","volume":"11","author":"Dholaria","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","article-title":"Principles and Therapeutic Applications of Adaptive Immunity","volume":"187","author":"Chi","year":"2024","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kanannejad, Z., Soleimanian, S., Ghahramani, Z., Sepahi, N., Mohkam, M., Alyasin, S., and Kheshtchin, N. (2023). Immune checkpoint molecules in prevention and development of asthma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1070779"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e70030","DOI":"10.1002\/mog2.70030","article-title":"Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics","volume":"4","author":"Sun","year":"2025","journal-title":"MedComm Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100021","DOI":"10.1016\/j.tmed.2026.100021","article-title":"Unlocking new horizons in immunity: The roles and mechanisms of immune checkpoints in inflammation regulation","volume":"1","author":"Song","year":"2026","journal-title":"TransMed"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-025-02332-6","article-title":"Immunological synapse: Structures, molecular mechanisms and therapeutic implications in disease","volume":"10","author":"Chao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"The UniProt Consortium (2025). UniProt: The Universal Protein Knowledgebase in 2025. Nucleic Acids Res., 53, D609\u2013D617.","DOI":"10.1093\/nar\/gkae1010"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13062-016-0159-9","article-title":"IPC\u2014Isoelectric Point Calculator","volume":"11","author":"Kozlowski","year":"2016","journal-title":"Biol. Direct"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/immuno4030013","article-title":"Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions","volume":"4","author":"Younis","year":"2024","journal-title":"Immuno"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory Mechanisms of Immune Checkpoints PD-L1 and CTLA-4 in Cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e70001","DOI":"10.1002\/ctd2.70001","article-title":"Challenges and Advances of Immune Checkpoint Therapy","volume":"4","author":"Li","year":"2024","journal-title":"Clin. Transl. Disc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","article-title":"Convergent inducers and effectors of T cell paralysis in the tumour microenvironment","volume":"25","author":"Hanahan","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune Checkpoint Blockade in Infectious Diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","first-page":"30","article-title":"Defining \u2019T cell exhaustion\u2019","volume":"5","author":"Blank","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The Next Decade of Immune Checkpoint Therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with Chemotherapy in the Era of Immune Checkpoint Inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A Comprehensive Review of Immune Checkpoint Inhibitors for Cancer Treatment","volume":"143","author":"Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_29","unstructured":"UniProtKB (2026, July 06). Q9Y5U5\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q9Y5U5\/entry."},{"key":"ref_30","unstructured":"UniProtKB (2026, July 06). P06729\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P06729\/entry."},{"key":"ref_31","unstructured":"UniProtKB (2026, July 06). P10747\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P10747\/entry."},{"key":"ref_32","unstructured":"UniProtKB (2026, July 06). Q9Y6W8\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q9Y6W8\/entry."},{"key":"ref_33","unstructured":"UniProtKB (2026, July 06). P43489\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P43489\/entry."},{"key":"ref_34","unstructured":"UniProtKB (2026, July 06). Q07011\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q07011\/entry."},{"key":"ref_35","unstructured":"UniProtKB (2026, July 06). P26842\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P26842\/entry."},{"key":"ref_36","unstructured":"UniProtKB (2026, July 06). P25942\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P25942\/entry."},{"key":"ref_37","unstructured":"UniProtKB (2026, July 06). Q15762\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q15762\/entry."},{"key":"ref_38","unstructured":"UniProtKB (2026, July 06). Q92956\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q92956\/entry."},{"key":"ref_39","unstructured":"UniProtKB (2026, July 06). P33681\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P33681\/entry."},{"key":"ref_40","unstructured":"UniProtKB (2026, July 06). P42081\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P42081\/entry."},{"key":"ref_41","unstructured":"UniProtKB (2026, July 06). O75144\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/O75144\/entry."},{"key":"ref_42","unstructured":"UniProtKB (2026, July 06). P23510\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P23510\/entry."},{"key":"ref_43","unstructured":"UniProtKB (2026, July 06). P41273\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P41273\/entry."},{"key":"ref_44","unstructured":"UniProtKB (2026, July 06). Q9UNG2\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q9UNG2\/entry."},{"key":"ref_45","unstructured":"UniProtKB (2026, July 06). P32970\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P32970\/entry."},{"key":"ref_46","unstructured":"UniProtKB (2026, July 06). P29965\u2014Homo Sapiens (Human). UniProtKB. Available online: https:\/\/www.uniprot.org\/uniprotkb\/P29965\/entry."},{"key":"ref_47","unstructured":"UniProtKB (2026, July 06). P19256\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P19256\/entry."},{"key":"ref_48","unstructured":"UniProtKB (2026, July 06). O43557\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/O43557\/entry."},{"key":"ref_49","first-page":"451","article-title":"Immune Checkpoint Inhibitors: Breakthroughs in Cancer Treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"ref_50","unstructured":"UniProtKB (2026, July 06). Q7Z6A9\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q7Z6A9\/entry."},{"key":"ref_51","unstructured":"UniProtKB (2026, July 06). P16410\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P16410\/entry."},{"key":"ref_52","unstructured":"UniProtKB (2026, July 06). Q15116\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q15116\/entry."},{"key":"ref_53","unstructured":"UniProtKB (2026, July 06). Q495A1\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q495A1\/entry."},{"key":"ref_54","unstructured":"UniProtKB (2026, July 06). P18627\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P18627\/entry."},{"key":"ref_55","unstructured":"UniProtKB (2026, July 06). Q8TDQ0\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q8TDQ0\/entry."},{"key":"ref_56","unstructured":"UniProtKB (2026, July 06). Q9H7M9\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q9H7M9\/entry."},{"key":"ref_57","unstructured":"UniProtKB (2026, July 06). Q6DKI7\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q6DKI7\/entry."},{"key":"ref_58","unstructured":"UniProtKB (2026, July 06). P13688\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P13688\/entry."},{"key":"ref_59","unstructured":"UniProtKB (2026, July 06). P40200\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P40200\/entry."},{"key":"ref_60","unstructured":"UniProtKB (2026, July 06). Q5ZPR3\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q5ZPR3\/entry."},{"key":"ref_61","unstructured":"UniProtKB (2026, July 06). Q7Z7D3\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q7Z7D3\/entry."},{"key":"ref_62","unstructured":"UniProtKB (2026, July 06). Q14242\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q14242\/entry."},{"key":"ref_63","unstructured":"UniProtKB (2026, July 06). O95971\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/O95971\/entry."},{"key":"ref_64","unstructured":"UniProtKB (2026, July 06). Q9NZQ7\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q9NZQ7\/entry."},{"key":"ref_65","unstructured":"UniProtKB (2026, July 06). Q9BQ51\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q9BQ51\/entry."},{"key":"ref_66","unstructured":"UniProtKB (2026, July 06). O00182\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/O00182\/entry."},{"key":"ref_67","unstructured":"UniProtKB (2026, July 06). Q08830\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q08830\/entry."},{"key":"ref_68","unstructured":"UniProtKB (2026, July 06). P15151\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/P15151\/entry."},{"key":"ref_69","unstructured":"UniProtKB (2026, July 06). Q92692\u2014Homo Sapiens (Human). Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q92692\/entry."},{"key":"ref_70","first-page":"84","article-title":"Regulatory Mechanisms of PD-1\/PD-L1 in Cancers","volume":"23","author":"Yang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sun, C., Mezzadra, R., and Schumacher, T.N. (2020). The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.568931"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"ref_74","first-page":"1474","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy","volume":"27","author":"Lee","year":"2019","journal-title":"Cell Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 Degradation Pathway and Immunotherapy for Cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Shin","year":"2017","journal-title":"Cell Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-024-00515-5","article-title":"Emerging Therapeutic Frontiers in Cancer: Insights into Posttranslational Modifications of PD-1\/PD-L1 and Regulatory Pathways","volume":"13","author":"Wang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e12767","DOI":"10.1111\/nan.12767","article-title":"Expression, Prognostic Significance and Therapeutic Implications of PD-L1 in Gliomas","volume":"48","author":"Vimalathas","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"100146","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-Mediated Inhibition of T Cell Activation: Mechanisms and Strategies for Cancer Combination Immunotherapy","volume":"3","author":"Liu","year":"2024","journal-title":"Cell Insight"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.14348\/molcells.2022.2056","article-title":"Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy","volume":"45","author":"Kim","year":"2022","journal-title":"Mol. Cells"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","article-title":"CD28 co-stimulation: Novel insights and applications in cancer immunotherapy","volume":"24","author":"Lotze","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-Expressed CTLA-4 Depletes CD80\/CD86 by Trogocytosis, Releasing Free PD-L1 on Antigen-Presenting Cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.17214","article-title":"The Role of CD28 in Adult T-Cell Leukaemia\/Lymphoma","volume":"192","author":"Nakahata","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"109482","DOI":"10.1016\/j.fsi.2024.109482","article-title":"The Interaction between the Costimulatory Molecules CD80\/86 and CD28 Contributed to CD4+ T Lymphocyte Activation in Flounder (Paralichthys olivaceus)","volume":"148","author":"Xing","year":"2024","journal-title":"Fish. Shellfish Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Battin, C., Leitner, J., Waidhofer-S\u00f6llner, P., Grabmeier-Pfistershammer, K., Olive, D., and Steinberger, P. (2022). BTLA Inhibition Has a Dominant Role in the Cis-Complex of BTLA and HVEM. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.956694"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ning, Z., Liu, K., and Xiong, H. (2021). Roles of BTLA in Immunity and Immune Disorders. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.654960"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Chang, M.-C., Lee, W.-C., Tai, Y.-J., and Chiang, Y.-C. (2025). BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy. Pharmaceuticals, 18.","DOI":"10.3390\/ph18121784"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"144953","DOI":"10.1016\/j.ijbiomac.2025.144953","article-title":"Targeting B and T Lymphocyte Attenuator in Cancer Immunotherapy","volume":"318","author":"Mortezaee","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-024-00556-2","article-title":"BTLA Biology in Cancer: From Bench Discoveries to Clinical Potentials","volume":"12","author":"Andrzejczak","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"103177","DOI":"10.1016\/j.jaut.2024.103177","article-title":"LIGHT Signaling through LT\u03b2R and HVEM in Keratinocytes Promotes Psoriasis and Atopic Dermatitis-like Skin Inflammation","volume":"144","author":"Gupta","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/or.2021.7943","article-title":"CD155\/TIGIT, a Novel Immune Checkpoint in Human Cancers (Review)","volume":"45","author":"Liu","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/s12276-024-01317-9","article-title":"Revisiting T-Cell Adhesion Molecules as Potential Targets for Cancer Immunotherapy: CD226 and CD2","volume":"56","author":"Jo","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2588717","DOI":"10.1080\/07853890.2025.2588717","article-title":"Immunotherapeutic Strategies Targeting the PVR\u2013TIGIT\/CD96\/CD226 Signaling Pathway in Glioma Treatment","volume":"57","author":"Qian","year":"2025","journal-title":"Ann. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, L., Li, B., Wang, Q., Chen, P., Shi, R., Zhou, X., Niu, X., Zhai, W., and Wu, Y. (2025). Identification of Epinastine as CD96\/PVR Inhibitor for Cancer Immunotherapy. BMC Biol., 23.","DOI":"10.1186\/s12915-025-02132-y"},{"key":"ref_98","first-page":"408","article-title":"Nectin Family of Cell-Adhesion Molecules: Structural and Functional Diversity","volume":"25","author":"Samanta","year":"2015","journal-title":"Trends Cell Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2253788","DOI":"10.1080\/19420862.2023.2253788","article-title":"Biophysical Characterization of PVR Family Interactions and Therapeutic Antibody Recognition to TIGIT","volume":"15","author":"Diong","year":"2023","journal-title":"mAbs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13046-021-02053-y","article-title":"The CD112R\/CD112 Axis: A Breakthrough in Cancer Immunotherapy","volume":"40","author":"Zeng","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Szereday, L., Nagy, D.U., Csiszar, B., Kevey, D., Feik, T., and Meggyes, M. (2021). Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111608"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in Cancer Immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5483\/BMBRep.2021.54.1.229","article-title":"Hitting the Complexity of the TIGIT-CD96-CD112R-CD226 Axis for Next-Generation Cancer Immunotherapy","volume":"54","author":"Jin","year":"2021","journal-title":"BMB Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","article-title":"The TIM3\/Gal9 Signaling Pathway: An Emerging Target for Cancer Immunotherapy","volume":"510","author":"Kandel","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A New Emerging Target in Cancer Immunotherapy: Galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2022","journal-title":"Genes Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 Teams up with PD-1 in Cancer Immunotherapy: Mechanisms and Perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"17512","DOI":"10.1038\/s41598-018-35754-0","article-title":"High Resolution X-ray and NMR Structural Study of Human T-Cell Immunoglobulin and Mucin Domain Containing Protein-3","volume":"8","author":"Gandhi","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41419-021-03689-6","article-title":"TIM-3 Drives Temporal Differences in Restimulation-Induced Cell Death Sensitivity in Effector CD8+ T Cells in Conjunction with CEACAM1","volume":"12","author":"Lake","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of Sabatolimab, a Novel Immunotherapy with Immuno-Myeloid Activity Directed against TIM-3 Receptor","volume":"2","author":"Schwartz","year":"2022","journal-title":"Immunother. Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 Regulates TIM-3-Mediated Tolerance and Exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3606362","DOI":"10.1155\/2023\/3606362","article-title":"CEACAM1 Is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Clear Cell Renal Cell Carcinoma","volume":"2023","author":"Yang","year":"2023","journal-title":"Dis. Markers"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"G\u00f6tz, L.G., Rueckschloss, U., Balk, G., Pfeiffer, V., Erg\u00fcn, S., and Kleefeldt, F. (2023). The Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295232"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 Promotes T Cell Responses and Autoimmunity by Repressing Tim-3\u2013Mediated Cell Death and Exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-Infiltrating DCs Suppress Nucleic Acid\u2013Mediated Innate Immune Responses through Interactions between the Receptor TIM-3 and the Alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","article-title":"TIM-3 as a Promising Target for Cancer Immunotherapy in a Wide Range of Tumors","volume":"72","author":"Sauer","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"107241","DOI":"10.1016\/j.jbc.2024.107241","article-title":"The Immune Checkpoint Receptor LAG3: Structure, Function, and Target for Cancer Immunotherapy","volume":"300","author":"Mariuzza","year":"2024","journal-title":"J. Biol. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-Like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Chocarro, L., Blanco, E., Zuazo, M., Arasanz, H., Bocanegra, A., Fern\u00e1ndez-Rubio, L., Morilla, I., Fern\u00e1ndez-Hinojal, G., Echaide, M., and Garnica, M. (2021). Understanding LAG-3 Signaling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105282"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1038\/s41467-024-51930-5","article-title":"Structural Basis for Mouse LAG3 Interactions with the MHC Class II Molecule I-Ab","volume":"15","author":"Ming","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ziogas, D.C., Theocharopoulos, C., Lialios, P.-P., Foteinou, D., Koumprentziotis, I.-A., Xynos, G., and Gogas, H. (2023). Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. Cancers, 15.","DOI":"10.3390\/cancers15102718"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ren, K., Hamdy, H., Meyiah, A., and Elkord, E. (2024). Lymphocyte-Activation Gene 3 in Cancer Immunotherapy: Function, Prognostic Biomarker and Therapeutic Potentials. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1501613"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","article-title":"Clinical Landscape of LAG-3-Targeted Therapy","volume":"14","author":"Chocarro","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"785091","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/cei.13415","article-title":"VISTA: Coming of Age as a Multi-Lineage Immune Checkpoint","volume":"200","author":"ElTanbouly","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a Ligand of VISTA Inhibits Human T-Cell Function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40364-024-00693-8","article-title":"A Pair of Promising Immune Checkpoints PSGL-1 and VISTA from Immunotolerance to Immunotherapy","volume":"12","author":"Peng","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","article-title":"VISTA Checkpoint Inhibition by pH-Selective Antibody SNS-101 with Optimized Safety and Pharmacokinetic Profiles Enhances PD-1 Response","volume":"15","author":"Thisted","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_128","first-page":"265","article-title":"The VISTA\/VSIG3\/PSGL-1 Axis: Crosstalk between Immune Effector Cells and Cancer Cells in Invasive Ductal Breast Carcinoma","volume":"73","author":"Alshaibi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"189351","DOI":"10.1016\/j.bbcan.2025.189351","article-title":"VISTA as a Context-Dependent Immune Checkpoint: Implications for Tumor Immunity and Autoimmune Pathogenesis","volume":"1880","author":"Niu","year":"2025","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Rev. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","article-title":"Control of Immunity by the TNFR-Related Molecule OX40 (CD134)","volume":"28","author":"Croft","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10555-024-10184-9","article-title":"OX40\/OX40 Ligand and Its Role in Precision Immune Oncology","volume":"43","author":"Thapa","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Zhang, J., Jiang, X., Gao, H., Zhang, F., Zhang, X., Zhou, A., Xu, T., and Cai, H. (2022). Structural Basis of a Novel Agonistic Anti-OX40 Antibody. Biomolecules, 12.","DOI":"10.3390\/biom12091209"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Sato, A., Nagai, H., Suzuki, A., Ito, A., Matsuyama, S., Shibui, N., Morita, M., Hikosaka-Kuniishi, M., Ishii, N., and So, T. (2025). Generation and Characterization of OX40-Ligand Fusion Protein That Agonizes OX40 on T-Lymphocytes. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1473815"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.2147\/OTT.S214211","article-title":"OX40 (CD134) and OX40 Ligand, Important Immune Checkpoints in Cancer","volume":"12","author":"Deng","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Yuan, Z., Pan, Y., Yuan, H., and Gong, A. (2025). OX40\/OX40L: A New Target for Tumor Immunotherapy and Its Clinical Research Progress. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1730620"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/16717","article-title":"ICOS Is an Inducible T-Cell Co-Stimulator Structurally and Functionally Related to CD28","volume":"397","author":"Hutloff","year":"1999","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e71467","DOI":"10.1002\/cam4.71467","article-title":"Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory System","volume":"15","author":"Nikanjam","year":"2026","journal-title":"Cancer Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e000544","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The Rationale behind Targeting the ICOS-ICOS Ligand Costimulatory Pathway in Cancer Immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41467-020-18828-4","article-title":"Structural Characterization of the ICOS\/ICOS-L Immune Complex Reveals High Molecular Mimicry by Therapeutic Antibodies","volume":"11","author":"Rujas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s12964-025-02559-4","article-title":"ICOSL: More than a Trigger of ICOS Function","volume":"23","author":"Stoppa","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Bartkowiak, T., and Curran, M.A. (2015). 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00117"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy Targeting 4-1BB: Mechanistic Rationale, Clinical Results, and Future Strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Salek-Ardakani, S., Zajonc, D.M., and Croft, M. (2023). Agonism of 4-1BB for immune therapy: A perspective on possibilities and complications. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1228486"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Zhao, P., Chen, K., Yang, L., Wan, C., Zhang, L., Luo, S., and He, X. (2025). Clinical and functional characterization of a novel TNFRSF9 variant causing immune dysregulation with predisposition to EBV-driven lymphomagenesis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1605221"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1007\/s00262-023-03548-7","article-title":"ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1","volume":"72","author":"Fritzell","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB Immunotherapy: Advances and Hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/eji.201445388","article-title":"Deciphering CD137 (4-1BB) Signaling in T-Cell Costimulation for Translation into Successful Cancer Immunotherapy","volume":"46","author":"Labiano","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_148","first-page":"eadf6692","article-title":"CD137 (4-1BB) Requires Physically Associated cIAPs for Signal Transduction and Antitumor Effects","volume":"10","author":"Zapata","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Chester, C., Sanmamed, M.F., Wang, J., and Melero, I. (2022). Targeting 4-1BB for Tumor Immunotherapy from Bench to Bedside. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.975926"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1038\/s41375-021-01287-1","article-title":"CD137 (4-1BB) Stimulation Leads to Metabolic and Functional Reprogramming of Human Monocytes\/Macrophages Enhancing Their Tumoricidal Activity","volume":"35","author":"Stoll","year":"2021","journal-title":"Leukemia"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"239083","DOI":"10.1155\/2010\/239083","article-title":"Glucocorticoid-Induced TNFR-Related (GITR) Protein and Its Ligand in Antitumor Immunity: Functional Role and Therapeutic Modulation","volume":"2010","author":"Placke","year":"2010","journal-title":"J. Immunol. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/s41467-021-21563-z","article-title":"Structures of Mouse and Human GITR\u2013GITRL Complexes Reveal Unique TNF Superfamily Interactions","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"100660","DOI":"10.1016\/j.xcrm.2022.100660","article-title":"Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates Fc\u03b3R-independent GITR agonism and antitumor activity","volume":"3","author":"Liu","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_154","unstructured":"Yin, X., Zhang, J., Li, Y., Wang, Y., and Guo, J. (2025). GITR\/GITRL Signaling in Cancer Immunotherapy: Biological Functions and Clinical Advances. Front. Immunol., 16."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"614","DOI":"10.18632\/oncotarget.28461","article-title":"Targeting GITR in Cancer Immunotherapy\u2014There Is No Perfect Knowledge","volume":"14","author":"Davar","year":"2023","journal-title":"Oncotarget"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14728222.2018.1512588","article-title":"Glucocorticoid-Induced TNFR-Related Gene (GITR) as a Therapeutic Target for Immunotherapy","volume":"22","author":"Schaer","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1476-5381.2011.01753.x","article-title":"Pharmacological Modulation of GITRL\/GITR System: Therapeutic Perspectives","volume":"165","author":"Nocentini","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Papadakos, S.P., Valsamidis, K., Misiakos, E.P., Schizas, D., Felekouras, E., and Moris, D. (2024). Exploring the Role of GITR\/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16142609"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1189\/jlb.0610351","article-title":"Role of CD27\/CD70 Pathway of Activation in Immunity and Tolerance","volume":"89","author":"Denoeud","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.4049\/jimmunol.0802809","article-title":"Protective CD8 T Cell Memory Is Impaired during Chronic CD70-Driven Costimulation","volume":"182","author":"Arens","year":"2009","journal-title":"J. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Wu, R., Chen, J., Wang, G., and Han, L. (2025). CD70 as a Target in Cancer Immunotherapy: Advances, Challenges, and Future Directions. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1609840"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-24-2668","article-title":"The CD70\u2013CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target","volume":"31","author":"Sam","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_163","first-page":"186","article-title":"Comprehensive Analysis of Prognosis and Immune Function of CD70-CD27 Signaling Axis in Pan-Cancer","volume":"23","author":"Liu","year":"2023","journal-title":"Funct. Integr. Genom."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.jbc.2021.101102","article-title":"Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complex","volume":"297","author":"Liu","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s42003-022-03182-6","article-title":"Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering","volume":"5","author":"Heckel","year":"2022","journal-title":"Commun. Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/s41467-023-37614-6","article-title":"Nasopharyngeal Carcinoma Cells Promote Regulatory T Cell Development and Suppressive Activity via CD70-CD27 Interaction","volume":"14","author":"Gong","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13046-024-03215-4","article-title":"Soluble and EV-Bound CD27 Act as Antagonistic Biomarkers in Patients with Solid Tumors Undergoing Immunotherapy","volume":"43","author":"Gorgulho","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular Basis and Therapeutic Implications of CD40\/CD40L Immune Checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1359-6101(03)00024-8","article-title":"The CD40\u2013CD154 Interaction in B Cell\u2013T Cell Liaisons","volume":"14","author":"Bishop","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","article-title":"Facts and Hopes of CD40 Agonists in Cancer Immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"eadl5815","DOI":"10.1126\/sciadv.adl5815","article-title":"Mechanotransduction governs CD40 function and underlies X-linked hyper-IgM syndrome","volume":"10","author":"Choi","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.jtauto.2025.100288","article-title":"The Role of Soluble CD40L in Autoimmune Diseases","volume":"10","author":"Mabrouk","year":"2025","journal-title":"J. Transl. Autoimmun."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e37718","DOI":"10.1097\/MD.0000000000037718","article-title":"Co-Stimulators CD40-CD40L, a Potential Immune-Therapy Target for Atherosclerosis: A Review","volume":"103","author":"Tian","year":"2024","journal-title":"Medicine"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Salomon, R., and Dahan, R. (2022). Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.940674"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41590-020-0770-x","article-title":"A Dynamic CD2 Rich Compartment at the Outer Edge of the Immunological Synapse Boosts and Integrates Signals","volume":"21","author":"Demetriou","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1083\/jcb.200809136","article-title":"The Coreceptor CD2 Uses Plasma Membrane Microdomains to Transduce Signals in T Cells","volume":"185","author":"Kaizuka","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/cb6002515","article-title":"Mechanisms of Cellular Avidity Regulation in CD2\u2013CD58-Mediated T Cell Adhesion","volume":"1","author":"Zhu","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","article-title":"The Immunological Synapse","volume":"2","author":"Dustin","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2024-206061","article-title":"Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies","volume":"144","author":"Carturan","year":"2024","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s41423-025-01314-6","article-title":"CD2 Augmentation Enhances CAR-T-Cell Efficacy via Immunological Synapse Remodeling and T-Cell Exhaustion Mitigation","volume":"22","author":"Zhu","year":"2025","journal-title":"Cell Mol. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1158\/1078-0432.CCR-15-2440","article-title":"Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target","volume":"23","author":"MacGregor","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/imr.12521","article-title":"The Third Group of the B7-CD28 Immune Checkpoint Family: HHLA2, TMIGD2, B7x, and B7-H3","volume":"276","author":"Janakiram","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s12672-026-04926-0","article-title":"Prognostic and Therapeutic Roles of B7-H3 and B7-H4 in Prostate Cancer","volume":"17","author":"Hu","year":"2026","journal-title":"Discov. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1038\/s41467-025-58740-3","article-title":"Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, X., Wang, H., Liu, J., Chen, Z., and Zhao, L. (2025). Immunological Mechanisms and Antibody-Drug Conjugates Targeting B7-H3 and B7-H4 in Ovarian Cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1683674"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune Checkpoint of B7-H3 in Cancer: From Immunology to Clinical Immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_188","first-page":"12775","article-title":"Roles of Coinhibitory Molecules B7-H3 and B7-H4 in Esophageal Squamous Cell Carcinoma","volume":"37","author":"Yonesaka","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An Attractive Target for Antibody-Based Immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune Checkpoint Therapy for Solid Tumours: Clinical Dilemmas and Future Trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune Checkpoint Signaling and Cancer Immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory Receptors and Ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or Backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"101831","DOI":"10.1016\/j.xcrm.2024.101831","article-title":"Analysis of PD1, LAG3, TIGIT, and TIM3 Expression in Human Lung Adenocarcinoma Reveals a 25-Gene Signature Predicting Immunotherapy Response","volume":"5","author":"Peyraud","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"101621","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and Prospects of Biomarkers for Immune Checkpoint Inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"14","DOI":"10.17305\/bb.2023.9265","article-title":"Refining PD-1\/PD-L1 Assessment for Biomarker-Guided Immunotherapy: A Review","volume":"24","author":"Zdrenka","year":"2024","journal-title":"Biomol. BioMed"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/imt-2022-0168","article-title":"Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis","volume":"15","author":"Zhou","year":"2023","journal-title":"Immunotherapy"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/5\/84\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:32:42Z","timestamp":1789032762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/5\/84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":198,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["antib15050084"],"URL":"https:\/\/doi.org\/10.3390\/antib15050084","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}